Oncology News | pharmaphorum

News

ASCO: Novartis’ Scemblix aces first-line CML study

Novartis’ first-in-class STAMP inhibitor Scemblix could be headed for use earlier in the treatment pathway for chronic myeloid leukaemia (CML).

News

Astellas refiles CLDN 18.2 cancer drug after FDA knockback

The US FDA has started a fresh review of Astellas' zolbetuximab, trying to become the first claudin (CLDN) 18.2-targeting drug to reach the US market, after turning it dow

News

Gilead’s Trodelvy woes rise with failed bladder cancer trial

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer.

News

First patient gets bowel cancer jab in NHS 'matchmaker' push

The first patient has received a personalised colorectal cancer vaccine, produced by BioNTech, as part of NHS England and Genomics England’s Cancer Vaccine Launch Pad (CVL

News

Lilly’s Retevmo cleared for RET-positive child cancers

The US FDA has given accelerated approval for Eli Lilly’s RET inhibitor as a treatment for various RET-altered paediatric cancers, making it the first drug in the class av

News

FDA sets date for Sarclisa in first-line multiple myeloma

Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority revi

ASCO: Novartis’ Scemblix aces first-line CML study

Astellas refiles CLDN 18.2 cancer drug after FDA knockback

Gilead’s Trodelvy woes rise with failed bladder cancer trial

First patient gets bowel cancer jab in NHS 'matchmaker' push

Lilly’s Retevmo cleared for RET-positive child cancers

FDA sets date for Sarclisa in first-line multiple myeloma

Amazon puts $100m into global health drive

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks